Skip to main content

Table 2 Changes in response indicators

From: The reduction in CD8+PD-1+ T cells in liver histological tissue is related to Pegylated IFN-α therapy outcomes in chronic hepatitis B patients

Characteristics

Antiviral therapy

Baseline

6 months

12 months

ALT normal/total [n (%)]

3/32 (9.4%)

12/32 (37.5%)

21/32 (65.6%)

AST normal/total [n (%)]

5/32 (15.6%)

10/32 (31.3%)

25/32 (78.1%)

HBV-DNA negative [n (%)]

0/32 (0%)

6/32 (18.8%)

10/32 (31.3%)

HBeAg seroconversion [n (%)]

0/32 (0%)

10/32 (31.3%)*

15/32 (46.9%)

Fibrosis improvement [n (%)]

0/32 (0%)

14/32 (43.8%)

NA

Inflammation improvement [n (%)]

0/32 (0%)

22/32 (68.8%)

NA

  1. * Represents p < 0.05. NA represents not available. A serum HBV-DNA level < 20 IU/mL was defined as the limit of detectability